Professional
Added to YB: 2024-06-18
Pitch date: 2024-06-17
CATX [bullish]
Perspective Therapeutics, Inc.
-66.2%
current return
Author Info
Trickle Research is an independent microcap research firm. Visit the website.
Company Info
Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States.
Market Cap
N/A
Pitch Price
$10.68
Price Target
22.50 (+523%)
Dividend
N/A
EV/EBITDA
N/A
P/E
-2.16
EV/Sales
112.85
Sector
Biotechnology
Category
growth
Perspective Therapeutics - price target and allocation increase
CATX: Raised price target to $22.50 & allocation to 5 on less dilution than expected, $240-250M cash raised YTD, promising 61.5% ORR in Ph2 NET trial despite recent weakness. Risks: More dilution, failed trials. 1:10 reverse split. Model: ~$500M revs, ~50% margins, $22.50 PT on ~20x P/E by 2032.
Read full article (7 min)